(cis-4-Isopropyl-cyclohexyl)-methyl-ether | 24470-18-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (cis-4-Isopropyl-cyclohexyl)-methyl-ether
• 英文别名: cis-4-Isopropyl-1-methoxy-cyclohexan
• CAS: 24470-18-6
• 化学式: C₁₀H₂₀O
• 分子量: 156.268
• InChiKey: VYOMKQBPPSPKOD-AOOOYVTPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.85
• 重原子数：
  11.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.23
• 氢给体数：
  0.0
• 氢受体数：
  1.0

反应信息

• 作为产物：
  描述：

  4-异丙基苯酚 在 镍 三氟化硼乙醚 、 氢气 作用下， 以 乙醚 为溶剂， 190.0 ℃ 、12.26 MPa 条件下， 生成 (cis-4-Isopropyl-cyclohexyl)-methyl-ether
  参考文献：
  名称：

  Hueckel,W.; Bross,R., Justus Liebigs Annalen der Chemie, 1963, vol. 664, p. 1 - 18

  摘要：

  DOI：

文献信息

• TYK2 INHIBITORS AND USES THEREOF
  申请人：Nimbus Lakshmi, Inc.

  公开号：US20200131201A1

  公开（公告）日：2020-04-30

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

  本发明提供了化合物、其组合物以及使用它们来抑制TYK2并治疗TYK2介导的疾病的方法。
• [EN] AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER<br/>[FR] COMPOSÉS AMINO-TRIAZOLOPYRIDINE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2018114999A1

  公开（公告）日：2018-06-28

  The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.

  该规范通常涉及公式(I)的化合物及其药用盐，其中R1和R2具有本规范中定义的任何含义。该规范还涉及使用这些化合物和其盐来治疗或预防DNA-PK介导的疾病，包括癌症。该规范进一步涉及包括这些化合物和盐的制药组合物；包含这些化合物和盐的试剂盒；制造这些化合物和盐的方法；制造这些化合物和盐的中间体；以及使用这些化合物和盐来治疗DNA-PK介导的疾病，包括癌症的方法。
• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：Constellation Pharmaceuticals, Inc.

  公开号：US20160158207A1

  公开（公告）日：2016-06-09

  The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R 1 -R 4 of formula (I) and R 1 -R 3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

  本发明涉及公式（I）或公式（II）的化合物及其盐，其中公式（I）的R1-R4和公式（II）的R1-R3具有以下定义的任何值，以及其组合物和用途。这些化合物可用作CBP和/或EP300的抑制剂。还包括含有公式（I）或公式（II）的化合物或其药学上可接受的盐的制药组合物，以及使用这些化合物和盐治疗各种CBP和/或EP300介导的疾病的方法。
• TYK2 inhibitors and uses thereof
  申请人：Nimbus Lakshmi, Inc.

  公开号：US10562907B2

  公开（公告）日：2020-02-18

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

  本发明提供了用于抑制 TYK2 和治疗 TYK2 介导的疾病的化合物、其组合物和使用方法。
• Tetrazole Compounds Which Selectively Modulate The CB2 Receptor
  申请人：ERMANN Monika

  公开号：US20120071529A1

  公开（公告）日：2012-03-22

  Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.